Study Objectives: Mounting evidence implicates disturbed sleep or lack of sleep as one of the risk factors for Alzheimer's disease (AD), but the extent of the risk is uncertain. We conducted a broad systematic review and meta-analysis to quantify the effect of sleep problems/disorders on cognitive impairment and AD. Methods: Original published literature assessing any association of sleep problems or disorders with cognitive impairment or AD was identified by searching PubMed, Embase, Web of Science, and the Cochrane library. Effect estimates of individual studies were pooled and relative risks (RR) and 95% confidence intervals (CI) were calculated using random effects models. We also estimated the population attributable risk. Results: Twenty-seven observational studies (n = 69 216 participants) that provided 52 RR estimates were included in the meta-analysis. Individuals with sleep problems had a 1.55 (95% CI: 1.25-1.93), 1.65 (95% CI: 1.45-1.86), and 3.78 (95% CI: 2.27-6.30) times higher risk of AD, cognitive impairment, and preclinical AD than individuals without sleep problems, respectively. The overall meta-analysis revealed that individuals with sleep problems had a 1.68 (95% CI: 1.51-1.87) times higher risk for the combined outcome of cognitive impairment and/or AD. Approximately 15% of AD in the population may be attributed to sleep problems.
INTRODUCTION
Alzheimer's disease (AD) is a neurodegenerative disorder afflicting approximately five million older Americans, with a projected annual incidence of one million cases in the United States by 2050.
1,2 AD and other dementias are associated with significant morbidity and mortality, with worldwide costs estimated at US$604 billion in 2010. 3 Preventive and/or therapeutic measures targeted at delaying or curing AD are therefore imperative to mitigate this societal burden.
Mounting evidence implicates disturbed sleep or lack of sleep as a risk factor for AD. Demented older adults exhibit significant sleep disturbance and unhealthy sleep patterns, including shorter sleep duration and fragmented sleep, [4] [5] [6] [7] altered circadian rest/activity patterns, 5 and elevated rates of sleep disordered breathing (SDB). 8, 9 It is estimated that about 45% of AD patients have sleep disturbances. 10, 11 However, the ultimate etiologic role of sleep in AD pathogenesis remains unknown. Sources of sleep disturbances in AD are thought to include degeneration of neural pathways that regulate sleepwake patterns and sleep architecture. 10, 12 Sleep disorders may also exacerbate cognitive symptoms through impairment of sleep-dependent memory consolidation processes. 13, 14 It is possible that circadian rhythms and sleep disorders have a causal role in the pathophysiology of AD. If this is true, they could be critical to the goal of preventing this disease because effective interventions exist to improve sleep. 15 Narrative review articles examining this association [16] [17] [18] [19] reflect the opinion and consensus among specialists that there is growing experimental and epidemiologic evidence for a close reciprocal association of cognitive impairment and AD with sleep problems and disorders. However, to date, no review has quantified the effect of having sleep problems and disorders on cognitive impairment and AD. In this context, we conducted a broad systematic review and meta-analysis to quantify the effect between sleep problems and disorders on cognitive impairment and AD.
METHODS
We conducted this review in accordance with the step-by-step guide for systematic reviews and meta-analysis by Pai et al. 20 and adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement by Moher et al. 21 and the Cochrane handbook.
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Identification of Eligible Studies
Electronic Search A broad search strategy was employed to identify all eligible published articles in scientific (medical, psychological, and epidemiological) journals up to November 2014. This strategy combined terms characterizing clinical AD or AD pathology as the outcome variable, sleep, as the exposure variable, and a third set of terms specifying specific study types including cross-sectional, case-control, cohort (retrospective and prospective), randomized clinical trials (RCTs), literature reviews, systematic reviews, and ecological studies. All terms within each set were combined with the Boolean operator OR, and the three sets were combined using AND. Articles were identified by searching four bibliographic databases on November 21, 2014:
• Medline (through PubMed; all years 1946-present)
• Articles written in other languages other than English were also considered and screened with the help of Google translator. The PubMed search (see Supplemental Table 1 in supplemental material) was adapted to searching the other databases.
Searching Other Sources
To locate additional relevant studies, the reference lists of articles identified through database searches and the bibliographies of narrative review articles were examined. We also hand-searched the previous year's issues (November 2013-November 2014) of high-ranking journals that published more than one relevant identified article during the initial search, for example, Sleep Medicine Reviews, Neurology, JAMA ( 
Selection Criteria
Type of Studies. Original articles from observational studies (cross-sectional, case-control, and retrospective/prospective cohort) and RCTs were included in this review. Eligible studies for the meta-analysis were required to (i) have reported a primary or secondary data analysis using any of the above-mentioned study design of any association of sleep problems or disorders with cognitive impairment or AD; (ii) have an explicit measure of cognitive impairment or AD (e.g., performance on individual cognitive tests, [PSG] ); (iv) study a comparison group without sleep problems or disorders in cohort studies; and (v) provide sufficient data to quantify the measure of association of sleep problems or disorders with cognitive impairment or AD. The following studies were excluded: (i) case series, case reports, narrative reviews, abstracts, or editorials and (ii) any RCT that did not examine the cognitive effects of treating sleep and its related problems or disorders in AD.
Sleep Problems and/or Disorders
Sleep problems and/or disorders were considered as the risk factor for interest in this systematic review. All sleep disorders described in the International Classification of Sleep Disorders version 2 23 were considered. Previous studies 24, 25 employed various concepts to define sleep problems in order to fit their study design. Accordingly, for subgroup analysis, we grouped eligible studies in this review measuring sleep using parameters such as quality, efficiency, and/or disturbance as sleep quality.
AD/Cognitive Impairment
The outcomes of interest in this review were cognitive impairment or AD. AD is the most common form of dementia accounting for up to 50%-80% of dementia cases. 2 Studies that solely looked at specific forms of dementia other than AD, for example, vascular, Lewy body, or frontotemporal dementia, were excluded.
Participants and Setting
Participants of the included studies were middle-aged and elderly adults of both sexes with age ranging from 40 to 91 years. Studies were considered from multiple continents, and no geographic restrictions were imposed.
Data Extraction
An independent assessment of all titles and abstracts of eligible studies identified by the search strategy was performed by two authors (OB and OU) using EndNote X6. Potential articles for the study were retrieved and examined for possible inclusion by the same two authors. Discordant decisions regarding inclusion were resolved by two other authors (YS and YW). Data extraction was performed by two authors (OB and OU). Extracted fields included study design, study population, exposure and outcome assessment, statistical methods and tests used, covariates, and the main results of the study. Differences in the information extracted were resolved by two other authors (YS and YW). Reviewers were not blinded to the funding, authors, or institutions.
Assessment of Study Quality
Study quality was assessed using an adaptation from previous systematic reviews 26, 27 and the modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational studies, 28, 29 with addition of new items relevant to this review. Parameters used for the quality assessment included well-specified hypothesis, study design type, appropriately described sample, sample size, definition of sleep and its related abnormalities, definition of cognitive impairment or AD, statistical analytic methods, and inclusion of or approach used to adjust for potential confounders. For each assessment category, a star rating system was used with specific maximum number of stars awarded (see Supplemental Table 2 ). Studies were divided into three categories: low quality (<50% of the maximum number of stars), medium quality (≈ 55%-70% of the maximum number of stars), and high quality (70% or more of the maximum number of stars).
Statistical Analysis
This systematic review consisted of both binary and continuous outcomes. Effect sizes from the reviewed studies included odds ratios (ORs), hazard ratios (HRs), Pearson's correlation coefficient (r), beta estimates (β), and standardized mean differences (d). To proceed with the meta-analysis, we converted the different indices to a common index: ORs (meta-analyses were computed using log(OR) but were converted back to odds for presentation; see Table S2 converting from β to OR (exp(β) (see Table S3 in supplemental material). 30 The question of whether or not it is appropriate to combine effect sizes from studies using varying metrics is under debate. We considered the fact that studies included in the review and subsequent analyses had to meet certain inclusion and exclusion criteria and were judged to be comparable in relevant ways. Since our aim was to compute a summary effect size of the impact of sleep problems on AD, we accounted for multiple outcome measures on the same subjects by computing the mean of the effect sizes for each study and used the average effect size as the unit of analysis (see Table S4 in supplemental material). For example, we pooled the effect estimates in a single study that had separate outcome measures using the MiniMental State Examination (MMSE) and the trail-making B test (Trails B) on the same subjects. 31 This influenced the calculation of the variance of the sum and mean effects of the correlated variables (see Table S5 in supplemental material). For our analysis, we worked with a plausible range of correlations ranging from 0.5 to 1.0 and performed sensitivity analyses to find the most appropriate standard error range. Our method could only have overestimated the variance and underestimated the precision of our summary effect. Individual studies that examined the effect of sleep on AD on different populations were treated as independent. [32] [33] [34] [35] [36] [37] [38] Reanalyses of reported effect estimates was conducted where appropriate in order to maintain consistency of definitions. For example, effect estimates for sleep duration of ≤5 hr, 6 hr, and for ≤6.5 hr were pooled to a single estimate for sleep duration of ≤6.5 hr. 32, 38, 39 Furthermore, we converted the risk estimate for better sleep consolidation to a risk estimate for poor sleep consolidation. 40 Participants in the reviewed studies were between the ages of 40 and 91. Because the prevalence of AD in this population and in the general population is just under 5%, 2 no relevant artificial bias was introduced by pooling effects from cohort studies with effects from case-control and cross-sectional studies. Therefore, we will refer to the pooled effect estimates as relative risks (RRs), understanding that these are estimated in some studies. Effect estimates of all individual studies were pooled and RR and 95% confidence intervals (CI) were calculated using random effects models. Heterogeneity of results across studies was assessed using chi-square test and quantified using I-square statistics. 41 Subgroup analyses were conducted to explore potential causes of heterogeneity. We anticipated heterogeneity and as such restricted subgroup analyses to situations where four or more studies were available per subgroup, because heterogeneity is better assessed with multiple studies. 41 Multivariate meta-regression analysis was also performed to examine the effect of possible influential factors (i.e., sex, mean age, sample size, and study quality). We assessed for publication bias using a funnel plot asymmetry test and trim-and-fill. Additionally, the population attributable risk percent (PAR%), which estimates the percentage of the outcome (AD) that would be prevented in the population if the exposure (sleep problems or disorders) was eliminated, was calculated. All statistical analyses were conducted using metaphor in R 42 and SAS 9.4. Figure 1 shows the study retrieval and selection process for the effects of sleep on cognitive impairment and/or AD. Of the 2341 publications identified initially from the literature search, 27 studies were included in the meta-analysis (Figure 1 ). A total of 1120 duplicates were removed. The remaining 1221 publications were screened for titles resulting in the exclusion of 180 publications. After this exclusion, 1041 publications were screened using published abstracts, resulting in the exclusion of 840 publications that were case series/reports, literature reviews, abstracts, or editorials. Two hundred and one full-text articles were assessed for eligibility, and 130 publications (105 observational studies and 25 RCTs) were further excluded because they were review articles, did not provide any measure of association, were not peer reviewed, or because sleep and AD were not assessed. One study was included from a search of the reference lists of articles identified through database searches. The remaining 72 studies were selected for the systematic review. For the meta-analysis, 45 publications were further excluded because they lacked sufficient information needed for a meta-analysis, were duplicate studies presenting similar or exact information from same study population, or had an experimental study design leaving 27 studies with 52 effect estimates.
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RESULTS
Study Selection
Study Characteristics
Design and Quality
Among the 27 studies identified for the meta-analysis, there were 8 cross-sectional, 31,37,44-49 1 case-control, 50 2 retrospective cohort, 33, 51 and 16 prospective cohort 32, 34, 36, [38] [39] [40] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] (Table 1) . Of these, 15 were considered to be of high quality, 10 were of medium quality, and 2 were of low quality. Selection bias related to sampling, measurements of sleep and/or AD solely based on self-report, and insufficient adjustment for core confounders were the main limitations. All of the included articles in the meta-analysis were written in English and published in peer-reviewed journals.
Participants and Setting
The 27 studies included in the meta-analysis were published between 2001 and 2014 and included a total of 69 216 participants from 4 continents ( Table 1) . Pooled RRs included 25 estimates from studies conducted in North America, 14 estimates from Europe, 1 from Australia, and 4 from Asia (Table 2) . Twenty-one studies included both sexes, of which three had separate analysis for men and women, five were limited to women, and one was limited to men (Table 1) .
Sleep Problems/Disorders
Sleep problems were based on a physician diagnosis (e.g., ICD-9 codes and apnea hypopnea index [AHI] scores for sleep apnea) or were assessed using self-reported questionnaires or interviews (Table 1) . There was considerable variability in the methods used to define and validate sleep problems. Nine studies utilized objective measures (e.g., wrist actigraphy or PSG), while seven studies utilized standardized questionnaires such as the PQSI or ESS. Five studies utilized self-constructed questionnaires and 1 study made use of fluorescence immuneassay (FIA) to determine melatonin/hypocretin concentrations. 50 Most studies reported risk estimates for individual symptoms. Multiple symptoms were also assessed in some studies. Sleep parameters assessed included (but were not limited to) sleep duration, sleep quality, daytime sleepiness, sleep latency, sleep efficiency, wake after sleep onset (WASO), sleep fragmentation, circadian rhythm abnormalities, obstructive sleep apnea (OSA), and insomnia. The interval over which sleep problems was assessed extended from about a week to a median of 12.5 years.
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Cognitive Impairment and/or AD There also was also significant variability in the methods used to diagnose cognitive impairment or AD. Most studies used self-reported diagnoses with information collected to determine whether they likely met standardized criteria (e.g., DSM-IV TR; Table 1 
Meta-Analysis
Overall Meta-Analysis Based on Risk Estimates for the Effect of Sleep on Cognitive Impairment and AD Sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA were associated with a significantly increased RR for the combined outcome of cognitive impairment and AD of 1.68 (95% CI: 1.51-1.87; Figure 2 Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer's disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to establish a registry for Alzheimer's disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschké selective reminding test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute of neurological and communicative disorders and stroke and the Alzheimer's disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and association internationale pour la recherché et l'enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau, phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire; TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset; WHIIRS, women's health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without. a Significant. b Multiple outcome measure on same subject, so mean of the outcome computed. Figure 3 ) These results highlight potential mechanistic relationships suggesting that sleep is not only associated with cognitive impairment or symptomatic AD but is also associated with changes in AD biomarkers predictive of persons who ultimately develop AD.
Funnel Plot Asymmetry Test and Trim-and-Fill Analysis Assessment of Publication Bias
Regarding possible publication bias, a funnel plot asymmetry test was significant (z = 5.5109, p < .0001), 62 indicating that some form of publication bias exist. Furthermore, a trim-andfill analysis 63 (which aims both to identify and correct for funnel plot asymmetry arising from publication bias by essentially "trimming" or removing the smaller studies causing funnel plot asymmetry, and then using the trimmed funnel plot to estimate the true 'center' of the funnel, while replacing the omitted studies and their missing "counterparts" around the center [filling]) imputed 17 unpublished studies and confirmed that in smaller studies, weaker effects were less often published (Figure 4) . The trim-and-fill results showed an estimated RR of 1.42 (95% CI: 1.28-1.58), suggesting that bias could reduce the size of the effect but is unlikely to explain it entirely. The trimand-fill method does not require any assumptions regarding mechanisms leading to bias in publication, rather it provides an estimate of the number of missing studies and calculates an estimated effect "adjusted" for the publication bias (based on the filled studies).
Subgroup Meta-Analysis Based on Risk Estimates for the Effect of Different Sleep Problems and Disorders on Cognitive Impairment and AD
Analyzing various sleep problems and disorders ( Figure 5 ), the highest RR for AD and/or cognitive impairment was noted for OSA (RR: 2.37, 95% CI: 1.82-3.08). The RR of cognitive impairment and/or AD associated with sleep quantity was 1 Subgroup analyses (Table 2) investigating various sleep parameters revealed that poor sleep efficiency was associated with the highest risk of cognitive impairment or AD, followed by sleep latency and WASO. Nighttime problems were associated with the strongest measure of effect for cognitive impairment or AD, with smaller effects seen for night-and daytime problems. When examined separately, men and women with sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA, each had similar RRs. The risk of cognitive impairment or AD due to sleep duration was higher in long sleepers (>8 hr/day) when compared to normal sleepers (7-8 hr/day), than in short sleepers (<7 hr/day). Studies with ≥5 years of follow-up reported higher RRs due to sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA, than those with <5 years of follow-up. Studies from North America and Europe reported similar RRs due to sleep problems. Prospective studies showed slightly lower RRs than nonprospective studies, perhaps indicating a problem with temporality. Finally, the estimated risk of cognitive impairment or AD due to sleep problems was lower in the high-quality studies than in the low-quality studies.
Subgroup Meta-Analysis Based on Risk Estimates for the Effect of Self-Report and Actigraphic Data of Poor Sleep on Cognitive Impairment and/or Alzheimer's Disease
Furthermore, we analyzed studies that generated data on total sleep times (measured actigraphically) and examined these effects separately in relation to cognition from more generally defined poor sleep or self-reported sleep durations ( Figure 5 ). The RR for cognitive impairment or AD associated with self-reported poor sleep was 1.49 (95% CI: 1.26-1.76), while actigraphic report was 1.80 (95% CI
Exploring Potential Causes of Heterogeneity
The overall meta-analysis included a wide array of studies including different measures with varying neurobiological substrates (breathing control in sleep, circadian rhythmicity, sleep durations, perceived sleep depth) as well as varying outcome measures of AD, including ICD-9/DSM diagnoses, cognitive tests, and abnormal proteins; and this could possibly be a potential source of heterogeneity. Therefore, we explored this and other potential causes for heterogeneity and conducted several subgroup meta-analyses (Figures 4-6 and Table 2 ; also see Figures S1-S3 in supplemental material). The differences seen across the subgroups failed to account for significant amounts of heterogeneity except for the varying outcome measures of AD and sample size. However, tendencies could be observed. As sample size increased, the effect size decreased. This agreed with the funnel plot. The varying outcome measures of AD accounted for 12.78% heterogeneity. Several of the other subgroup analyses were close to being statistically significant; however, there were only 52 effect sizes in the analysis, so power may have been an issue for some subanalyses.
Sensitivity Analyses
Sensitivity analysis incorporating only studies that examined the relationship between sleep and cognitive impairment and/or symptomatic AD for the overall meta-analysis yielded an RR of 1.62 (95% CI: 1.45-1.80), suggesting that exclusion of studies that examined sleep associations with preclinical AD could reduce the overall effect size; however, the change in effect size was not statistically significant. Similarly, removing effect estimates of outliers from the analysis had no significant effect on the pooled RR (RR: 1.62, 95% CI: 1.47-1.79). Furthermore, exclusion of studies examining sleep associations with preclinical AD for the subgroup meta-analysis based on risk estimates for the effect of different sleep problems and disorders on cognitive impairment and AD produced similar RRs for the relationships between OSA, sleep quantity, sleep quality, insomnia, and cognitive impairment and/or AD.
As noted in the Funnel Plot Asymmetry test subsection, sensitivity analyses incorporating the 17 studies imputed by trimand-fill analysis showed an estimated RR of 1.42 (95% CI: 1.28-1.58), suggesting that bias could reduce the size of the effect but is unlikely to explain it entirely. It should also be noted that in the small sample, large effect size studies were mostly based on results of studies in which correlations were converted to ORs, so there may be a methodological explanation of funnel asymmetry other than bias. Altogether, the results support an association between sleep problems and cognitive impairment or AD. Despite possible publication bias and evidence of heterogeneity in the effect sizes, the overall association between sleep problems and cognitive impairment or AD remained positive in all sensitivity analyses.
Furthermore, we clearly understand that testing for heterogeneity may not explain the variability in the data because its basis may not simply be empirical but more fundamentally conceptual; therefore, we conducted several sensitivity analyses on both our exposure and outcome. Sensitivity analyses examining the effect of omitting one study revealed no effect as the estimated RR remained stable (See Figure S4 in supplemental material) . Sensitivity analyses were also conducted to see if all of the subcategories of exposure can be combined into one exposure. We examined the effect of the exposure on cognitive impairment and AD initially combined as presented in the overall meta-analysis ( Figure 2 ) and also while excluding each subcategory (Sleep Quality, Sleep Quantity, Obstructive Sleep Apnea, Circadian Rhythm Abnormalities, and Insomnia) from the exposure one at a time. No significant change in the effect size was seen. We also conducted separate analyses of studies in terms of the outcome measure, since different outcome measures of cognitive impairment and AD was used. We conducted analyses with the combined outcome of cognitive impairment and AD and also examined the change in the estimate while excluding each subcategory (cognitive tests, ICD-9/DSM-IV, and abnormal proteins). No statistically significant difference was observed in the change in effect estimate (Type I error rate (α = .05)).
Meta-Regression Analysis
A multivariate meta-regression analysis (Table 3) was conducted to examine the potential influence of different factors on the natural logarithm of the OR of sleep problems with cognitive impairment or AD. None of the studied factors was statistically significant except for sample size (p = .01), with larger samples showing smaller effects.
Population Attributable Risk Percentage
The PAR% suggested that approximately 15% of AD may be attributed to sleep problems, using a conservative estimate of 30% as the prevalence of sleep problems in the populations of the included studies and the pooled RR (RR: 1.55). By comparison, the prevalence of sleep problems in AD ranges between 25% and 50%.
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DISCUSSION
Summary of the Main Results
In the present meta-analysis comprising 27 studies, individuals with sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA had a 1.68 times higher risk for the combined outcome of cognitive decline and AD compared to individuals without sleep problems. Individuals with sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA, had a 1.55, 1.65, and 3.78 times higher risk for AD, cognitive impairment, and preclinical AD than individuals without sleep problems, respectively. A subgroup meta-analysis of classified sleep disorders revealed an RR of 2.37 for OSA, 1.86 for sleep duration problems, 1.62 for sleep quality problems, and 1.38 for both insomnia and circadian rhythm abnormalities. Various aspects of sleep problems examined in this analysis each significantly increased the risk of cognitive impairment or AD. Approximately 15% of cognitive impairment or AD may be attributed to sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA.
Effect of Sleep Problems on Cognitive Impairment or AD (MetaAnalysis)
Altogether, sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia, and OSA significantly increased cognitive impairment or AD risk. Our findings show an RR increase seemingly inverse to diagnostic confidence (e.g., 1.55, 1.65, and 3.78 for AD, cognitive impairment, and preclinical AD, respectively). The RR of 3.78 finding may reflect the use of more objective investigative or diagnostic measures to identify individuals with sleep problems and preclinical AD among studies that examined this association. Sample size may also have been responsible, as this was noted in our study to have significantly influenced the effect size such that larger sample size studies tended to result in smaller risk and vice versa. Overall, our results highlight potential mechanistic relationships, suggesting that sleep is not only associated with cognitive impairment or symptomatic AD but is also associated with changes in AD biomarkers predictive of persons who ultimately develop AD. Although there was heterogeneity in effect sizes, the variables included in the meta-analysis failed to explain significant amounts of this variability. OSA appeared to be a strong risk factor for AD. This may be explained by the fact that hypoxia plays a vital role and may contribute to increases in Aβ production, 64, 65 thereby facilitating AD pathogenesis. 66 Insomnia and circadian rhythm abnormalities were each associated with an intermediate risk of cognitive impairment or AD. Sleep quantity and quality seemed more important than insomnia and circadian activity rhythm as a risk factor for cognitive impairment or AD. This could be because individuals with insomnia and/or circadian rhythm abnormalities tend to have poor sleep quantity and quality and as such the effect seen could possibly reflect other underlying sleep problems such that individuals in the sleep quantity or quality groups may also have associated insomnia and/or circadian rhythm abnormalities. Both long sleep (>8 hr/day) and short sleep duration (<7 hr/day) increased the risk of cognitive impairment or AD when compared to normal sleepers (7-8 hr/day), with a higher risk seen in long sleepers. Although certain prospective studies have shown associations between long sleep and cognitive impairment, 67, 68 it is highly plausible that this association is a result of a general decline with old age and maybe reflective of other disease conditions such as depression or other neurological disorders. AD patients, like in Parkinson's disease, may also exhibit a bimodal distribution of sleep patterns (i.e., short or long) possibly indicative of some preexisting predisposition that develops at disease inception.
Potentially Influencing Factors (Meta-Regression Analysis)
The heterogeneity seen across studies could not be explained by our subgroup meta-analyses, except for sample size and the different AD measures. It is likely that much of the heterogeneity can be explained by the conceptual differences in exposure and/ or outcome assessment. We explored this further by conducting several sensitivity analyses on both our exposure and outcome, each initially combined as presented in the overall meta-analysis and also with exclusion of each subcategory one at a time. No significant change in the effect size was seen. Sensitivity analyses examining the effect of omitting one study revealed no effect as the estimated RR remained stable. Several of the subgroup analyses were close to being statistically significant. However, since there were only 52 effect sizes in the analysis, power may have been an issue. Pooled RRs from subgroup meta-analyses for the effect of sleep problems on cognitive impairment or AD revealed consistent moderate to strong RR, and these relationships could possibly contribute to a causal interpretation of the findings. No RCT was included, suggesting that additional work examining the effect of sleep therapy on cognitive impairment or AD would be useful.
Among the factors tested, only sample size significantly influenced the effect size between sleep problems and AD such that larger sample size studies tended to result in smaller risk estimates for cognitive impairment or AD, while smaller sample size studies tended to result in larger risk estimates for cognitive impairment or AD (Table 3) . Overall, the results indicate that the meta-analyzed estimate reflects an appropriate estimate of the general association. The need for proper multivariate modeling approaches is underscored by the fact that the heterogeneity due to adjustment was close to statistical significance in some instances, although power was limited.
Study Results in Comparison to Other Reviews on the Topic
The results of this systematic review and meta-analysis are largely consistent with previous reviews. Our study is the first systematic review and meta-analysis to quantify an "average" magnitude of the association between sleep problems and cognitive impairment or AD. Previous narrative review articles that have examined this association did so with a focus on different aspects of sleep disturbances/disorders. [16] [17] [18] [19] Palma et al., 16 focusing on sleep deprivation, reviewed how sleep loss constitutes a risk factor for various neurologic diseases including AD. Slats et al., 18 focusing on the role of hypocretin and melatonin, concluded that there is substantial evidence for impairments in both sleep and circadian regulating mechanisms resulting from AD pathology, which may be linked to clinical symptoms. Peter-Derex et al. 17 performed a thorough clinical review of sleep and AD, observing that micro-architectural sleep alterations, nocturnal sleep fragmentation, decreased sleep duration, diurnal napping, and inversion of the sleep-wake cycle are the main disorders observed in patients with AD. Spira et al. 19 concluded that poor sleep is a risk factor for cognitive impairment and AD and that healthy sleep appears to play an important role in maintaining brain health with age and could play a key role in AD prevention. Various reviews 69, 70 on the effect of OSA on AD agree on a bidirectional relationship between these entities.
Strengths and Limitations of the Study
Our systematic review allows for a systematic, scientific, constructive, and yet replicable review of the association between sleep and AD with a prespecified hypothesis and specific inclusion and exclusion criteria. We were able to systematically and efficiently integrate existing information from various studies enabling us to establish whether the literature is consistent and can be generalized across populations, settings, and/or whether findings vary significantly by particular subsets. The meta-analyses in particular increased the power and precision of estimates of the risk of cognitive impairment or AD from sleep problems. The explicit methods employed in our meta-analysis limit bias and, hopefully, improved reliability and accuracy of our conclusions. Finally, the generalizability of our findings can be established, as this review included a diversity of studies across various continents, providing an interpretive context not available in any one study.
Several methodological concerns must be considered when interpreting the findings of this meta-analysis. First, one potential limitation relates to the possible bias introduced in the paper selection process. To minimize this bias, we adhered strictly to the guidelines and recommendations in the Cochrane handbook 22 whenever possible. We also ensured that studies were not restricted by language to guard against language bias. Second, the possible bias introduced by the individual studies that were included is a further limitation. Various study designs were rated low for assigning the grade of evidence. 71 With a scarcity of controlled studies, this analysis relied mostly on observational studies. However, the subgroup meta-analysis revealed no significant difference between the prospective and nonprospective studies, suggesting that our average estimate adequately reflects the general effect. In addition to study design, conclusions made from the poor quality studies could introduce possible bias. We included high-, medium-, and low-quality studies in the summarization of findings. Our meta-regression analysis indicated that study quality might not have influenced the overall conclusion. Third, there was considerable variability between the studies in the assessment methods used to verify sleep problems and AD or cognitive impairment, revealing moderate heterogeneity that could possibly raise questions about the comparability of results across studies. Our research question focused on a broad concept of sleep problems based on having any symptoms. Thus, we assumed a common underlying concept by making general conclusions regarding sleep problems and cognitive impairment or AD. We based our assumption on findings from reviews that consistently found associations of various sleep problems or disorders such as sleep deprivation/loss, 16, 19 sleep-wake abnormalities, 17, 18 
